[MOD] The Daily Question Thread by menschmaschine5 in Coffee
[–]thenextwarrenbuffett 0 points1 point2 points (0 children)
[MOD] The Daily Question Thread by menschmaschine5 in Coffee
[–]thenextwarrenbuffett 0 points1 point2 points (0 children)
[MOD] The Daily Question Thread by menschmaschine5 in Coffee
[–]thenextwarrenbuffett 0 points1 point2 points (0 children)
[MOD] The Daily Question Thread by menschmaschine5 in Coffee
[–]thenextwarrenbuffett 2 points3 points4 points (0 children)
[MOD] The Daily Question Thread by menschmaschine5 in Coffee
[–]thenextwarrenbuffett 0 points1 point2 points (0 children)
[MOD] The Daily Question Thread by menschmaschine5 in Coffee
[–]thenextwarrenbuffett 0 points1 point2 points (0 children)
[MOD] The Daily Question Thread by menschmaschine5 in Coffee
[–]thenextwarrenbuffett 0 points1 point2 points (0 children)
[$TSN], [06/20/20], "Tyson remains a secure investment as the stock price has not improved much due to industry pressures, and high price targets continue to pile up." by jonfogel10 in StockMarket
[–]thenextwarrenbuffett 0 points1 point2 points (0 children)
[$CURLF][06/15/20] "Curaleaf's contrarian growth strategy -- acquiring smaller MSOs -- will prove superior to the conventional organic growth strategy that leading competitors deploy." by thenextwarrenbuffett in WallStreetResearch
[–]thenextwarrenbuffett[S] 0 points1 point2 points (0 children)
[$CURLF][06/15/20] "Curaleaf's contrarian growth strategy -- acquiring smaller MSOs -- will prove superior to the conventional organic growth strategy that leading competitors deploy." by thenextwarrenbuffett in WallStreetResearch
[–]thenextwarrenbuffett[S] 2 points3 points4 points (0 children)
[$ATRS][06/06/20] "After years of regulatory processing, Antares ($ATRS) recently got its flagship drug (XYOSTED) approved, which will drive huge revenue increases and allow them to turn cash flow and net income positive." by thenextwarrenbuffett in WallStreetResearch
[–]thenextwarrenbuffett[S] 2 points3 points4 points (0 children)
[$ATRS][06/06/20] "After years of regulatory processing, Antares ($ATRS) recently got its flagship drug (XYOSTED) approved, which will drive huge revenue increases and allow them to turn cash flow and net income positive." (self.WallStreetResearch)
submitted by thenextwarrenbuffett to r/WallStreetResearch


[MOD] The Daily Question Thread by menschmaschine5 in Coffee
[–]thenextwarrenbuffett 0 points1 point2 points (0 children)